Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 467

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 467
---
 working capital is insufficient for its current operational requirements, making it dependent on raising additional funds. It plans to secure financing through private equity placements, registering shares on public stock exchanges, or raising capital from its existing shareholders. Kadimastem’s future capital requirements will be affected by many factors, including Kadimastem’s revenue growth, the timing and extent of investments to support such growth, the development and regulatory approval of Kadimastem’s products, and many other factors as described under “Risk Factors.” To the extent additional funds are necessary to meet Kadimastem’s long -termliquidity needs as Kadimastem continues to execute Kadimastem’s business strategy, and cannot generate significant recurring revenues, profit and cash flow provided by operating activity, Kadimastem anticipates that they will be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds. However, such financing may not be available on favorable terms, or at all. In particular, the repercussions from inflation, economic uncertainty, as well as the war between Russia and the Ukraine and Israel, Hamas and Hezbollah, has resulted in, and may continue to result in, significant disruption of global financial markets, reducing Kadimastem’s ability to access capital. If Kadimastem is unable to raise additional funds when desired, Kadimastem’s business, financial condition and results of operations could be adversely affected. Cash and Cash Equivalents The balance of cash and cash equivalents for the year ended December31, 2024, was $650,398, representing a decrease of $495,177 compared to $1,145,575 for the year ended December31, 2023. The decrease is primarily due to the receipt of $1.7million under a convertible loan agreement between Kadimastem and its shareholders, Alpha and Mr.Julien Ruggieri, of which $1.25million was received on December21, 2023, and $450,000 was received on April20, 2024. The balance of cash and cash equivalents for the year ended December31, 2023, was $1,145,575, representing a decrease of $670,850 (37%), compared to $1,816,425 for the year ended December31, 2022. The decrease is primarily due to the net use of cash for operating activities. Net Cash Used in Operating Activities Net cash used in operating activities for the year ended December31, 202